Tevard Biosciences was established by Professor Harvey Lodish, Daniel Fischer, and Warren Lammert, who have children affected by Dravet syndrome, partnering with the renowned MIT molecular cell biologist. Their objective is to pioneer innovative gene therapy methods to treat various genetic diseases, including Dravet syndrome. Tevard has formed a team comprising leading experts from scientific, clinical, and industry fields to deliver tRNA gene therapies to patients within a critical timeframe. The company focuses on developing tRNA-based gene therapies for rare and severe genetic diseases with limited or no approved treatment options.